Experienced in Chronic Obstructive Pulmonary Disease (COPD)

Naushad Hirani

Calgary, AB, CA 
Experienced in Chronic Obstructive Pulmonary Disease (COPD)
Calgary, AB, CA 
OverviewLocationsClinical Research

Overview

Naushad Hirani practices in Calgary, Canada. Hirani is rated as an Experienced expert by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). Their top areas of expertise are Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Interstitial Lung Disease, Acute Interstitial Pneumonia, and Lung Transplant.

Their clinical research consists of co-authoring 15 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles and participated in 1 clinical trial in the study of Chronic Obstructive Pulmonary Disease (COPD).

Locations

Calgary, AB, Canada
Other Locations
Calgary, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs
Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs
Enrollment Status: Terminated
Publish Date: January 31, 2025
Intervention Type: Biological
Study Drug: Autologous EPCs transfected with human eNOS
Study Phase: Phase 2/Phase 3
Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data
Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Other
Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Withdrawal Study of Pulmonary Arterial Hypertension(PAH) Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric Oxide (INO)
Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Withdrawal Study of Pulmonary Arterial Hypertension(PAH) Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric Oxide (INO)
Enrollment Status: Withdrawn
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

15 Total Publications

Study of angiogenic cell therapy for progressive pulmonary arterial hypertension: intervention with repeat dosing of eNOS-enhanced EPCs: the SAPPHIRE trial.
Study of angiogenic cell therapy for progressive pulmonary arterial hypertension: intervention with repeat dosing of eNOS-enhanced EPCs: the SAPPHIRE trial.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: February 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hirani's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile